To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.
It falls into the class III antiarrhythmic agents because it inhibits the inward potassium ion channels in the heart. It is also a beta blocker because of its primary action on the β-adrenergic receptors in the heart.
By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.
It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).
Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.
Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sotalol". A list of authors is available in Wikipedia.|